Table 1.

Association of Galectin-3 expression with clinicopathological features in patients with HCC from training, testing and vascular invasion sets.

	Training set (n = 278)					Testing set (n = 90)					Vascular invasion (n = 62)
		Galectin-3 expression (n = 278)					Galectin-3 expression (n = 90)					Galectin-3 expression (n = 62)
Characteristic	Total	Low n = 143 (51.4%)	High n = 135 (48.6%)	χ2	P-value	Total	Low n = 51 (56.7%)	High n = 39 (43.3%)	χ2	P-value	Total	Low n = 19 (30.6%)	High n = 43 (69.4%)	χ2	P-value
Age, years
≥50	121	65	56	0.4459	0.5043	53	27	26	1.72	0.1897	38	14	24	1.77	0.1829
<50	157	78	79			37	24	13			24	5	19
Gender
Male	232	121	111	0.288	0.5915	10	6	4	0.05	0.8215	34	7	27	3.58	0.0584
Female	46	22	24			80	45	35			28	12	16
HBsAg
Positive	245	124	121	0.5646	0.4524	70	40	30	0.03	0.8646	50	13	37	2.62	0.1053
Negative	33	19	14			20	11	9			12	6	6
Liver cirrhosis
Yes	175	82	93	3.969	0.0463	80	47	33	1.27	0.2593	48	18	30	3.38	0.0660
No	103	61	42			10	4	6			14	1	13
Tumour size
≥5 cm	165	70	95	13.21	0.0003	35	14	21	6.48	0.0109	43	10	33	3.60	0.0576
<5 cm	113	73	40			55	37	18			19	9	10
Tumour number
Multiple	105	43	62	7.428	0.0064	11	6	5	0.02	0.8796	20	2	20	7.45	0.0063
Single	173	100	73			79	45	34			40	17	23
AFP
≥400 ng/ml	119	63	56	0.188	0.6646	32	20	12	0.69	0.4068	29	7	22	1.09	0.2975
<400 ng/ml	159	80	79			58	31	27			33	12	21
Histological differentiation
Well	50	30	20	1.789	0.1811	34	24	10	4.31	0.0378	33	11	22	0.24	0.6243
Poor	228	113	115			56	27	29			29	8	21
Tumour encapsulation
Yes	157	77	80	0.8278	0.3629	43	26	27	0.48	0.4867	36	11	25	0.0003	0.9856
No	121	66	55			47	25	22			26	8	18
TNM stage
I	174	105	69	15.45	<0.0001	58	39	19	7.43	0.0064	41	13	28	7.06	0.7999
II or III	103	37	66			32	12	20			21	6	15
Vascular invasion
Yes	41	13	28	7.496	0.0062	21	6	15	8.80	0.0030
No	237	130	107			69	45	24

Statistically significant values are in bold.